BioNexus Gene Lab EBITDA 2019-2024 | BGLC

Prices Financials Revenue & Profit Assets & Liabilities Margins Price Ratios Other Ratios Other Metrics

Revenue Gross Profit Operating Income EBITDA Net Income Shares Outstanding

BioNexus Gene Lab ebitda from 2019 to 2024. Ebitda can be defined as earnings before interest, taxes, depreciation and amortization.

Prices Financials Revenue & Profit Assets & Liabilities Margins Price Ratios Other Ratios Other Metrics

Revenue Gross Profit Operating Income EBITDA Net Income Shares Outstanding

BioNexus Gene Lab ebitda from 2019 to 2024. Ebitda can be defined as earnings before interest, taxes, depreciation and amortization.

Related Stocks
Company Name	Market Cap
Elevance Health (ELV)	$93.4B
Cencora (COR)	$48.3B
DiDi Global (DIDIY)	$22.2B
Natera (NTRA)	$22.1B
ICON (ICLR)	$17.7B
Viatris (VTRS)	$16B
Avantor (AVTR)	$14.1B
Revvity (RVTY)	$13.6B
CochLear (CHEOY)	$12.8B
Solventum (SOLV)	$12.2B
BioMerieux (BMXMF)	$11.9B
Medpace Holdings (MEDP)	$10.5B
Charles River Laboratories (CRL)	$10B
HealthEquity (HQY)	$9.1B
Doximity (DOCS)	$9B
Sonic Healthcare (SKHHY)	$8.9B
Bausch + Lomb (BLCO)	$6.9B
Life Times (LTH)	$5.1B
Organon (OGN)	$3.9B
Sotera Health (SHC)	$3.6B
BrightSpring Health Services (BTSG)	$3.3B
Surgery Partners (SGRY)	$2.9B
Concentras Parent (CON)	$2.8B
PACS (PACS)	$2.5B
Alignment Healthcare (ALHC)	$2.3B
Ardent Health Partners (ARDT)	$2.3B
Premier (PINC)	$2.2B
GeneDx Holdings (WGS)	$2.2B
Ryman Healthcare (RYHTY)	$2B
GoodRx Holdings (GDRX)	$1.9B